Stress Granules In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. RNA helicases like DDX55 (a DEAD-box helicase) are involved in RNA granule assembly and may contribute to RNP granule dysfunction in neurodegeneration.. This page provides detailed information about its structure, function, and role in disease processes.
Stress granules (SGs) are membraneless cytoplasmic ribonucleoprotein (RNP) condensates that form rapidly when cells encounter environmental stressors such as oxidative stress, heat shock, viral infection, or nutrient deprivation. They assemble through liquid-liquid phase separation (LLPS) of RNA-binding proteins (RBPs) and stalled translation pre-initiation complexes. Under normal conditions, SGs are transient and cytoprotective—they sequester non-essential mRNAs while allowing preferential translation of stress-response transcripts. However, when SG dynamics become dysregulated, particularly under chronic or repeated stress, they can serve as nucleation sites for pathological protein aggregation. This pathological transition has emerged as a central theme in the molecular pathogenesis of [amyotrophic lateral sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [Frontotemporal Dementia (FTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, and other [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases.
SG assembly is orchestrated by a set of core RNA-binding proteins that drive phase separation:
G3BP1/G3BP2 (Ras GTPase-Activating Protein-Binding Proteins): The primary nucleators of SG assembly. G3BP1 undergoes conformational changes upon stress that expose its intrinsically disordered regions (IDRs), promoting multivalent RNA–protein interactions and LLPS. Knockout of both G3BP1 and G3BP2 abolishes canonical SG formation (Kedersha et al., 2016 [1]).
TIA-1/TIAR (T-Cell Intracellular Antigen 1/TIA1-Related Protein): Upon stress, TIA-1 and TIAR translocate. TIA1L (TIA1-like) is a related protein involved in stress granule dynamics. from the nucleus to cytoplasmic SGs, where they bind AU-rich elements in the 3' UTRs of mRNAs stalled at the 48S pre-initiation complex. TIA-1 contains a prion-like domain (PrLD) critical for SG nucleation (Gilks et al., 2004 [2]).
[TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--: TAR DNA-binding protein 43, a predominantly nuclear RBP, is recruited to SGs under stress. [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- contains a glycine-rich C-terminal low-complexity domain that mediates phase separation. Disease-linked mutations in this domain (e.g., A315T, M337V, Q331K) accelerate SG maturation and reduce their dynamic exchange with the surrounding cytoplasm (Conicella et al., 2016 [3]).
[FUS[/entities/[fus[/entities/[fus[/entities/[fus--TEMP--/entities)--FIX-- (Fused in Sarcoma): FUS contains an N-terminal prion-like domain, an RNA-recognition motif, and RGG-rich regions that drive LLPS. ALS-linked FUS mutations (e.g., P525L, R521G) impair nuclear import, increasing cytoplasmic concentration and promoting aberrant SG incorporation (Patel et al., 2015 [4]).
SGs exhibit a core–shell architecture:
The primary SG nucleation pathway involves phosphorylation of the translation initiation factor eIF2α at Ser51 by one of four stress-responsive kinases:
Phosphorylated eIF2α blocks the GDP–GTP exchange activity of eIF2B, stalling translation at the 48S pre-initiation complex. The resulting pool of untranslated mRNPs provides the substrate for LLPS-driven SG condensation (Anderson & Kedersha, 2008 [6]).
SGs can also form independently of eIF2α phosphorylation through:
These non-canonical mechanisms are particularly relevant to neurodegeneration, as they can be triggered by [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX-- and [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- commonly observed in aging [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--.
Under acute stress, SGs rapidly assemble and disassemble within minutes to hours, maintaining liquid-like properties with rapid internal molecular exchange (residence times of 10–30 seconds for most components). However, chronic or repeated stress promotes a pathological transition:
Liquid-to-solid transition: SGs lose their dynamic liquid-like properties and adopt gel-like or solid-like states. This "maturation" or "aging" process is accelerated by disease-linked mutations in SG-resident proteins (Murakami et al., 2015 [7]).
[Amyloid] fibril nucleation: The prion-like domains of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--, FUS, TIA-1, and hnRNPA1 can undergo conformational changes within the concentrated SG environment, seeding amyloid-like fibrillar structures that resist normal SG disassembly (Lin et al., 2015 [8]).
Impaired clearance: Aged SGs become resistant to normal disassembly machinery, including chaperones ([heat shock proteins) and [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- pathways. The VCP/p97 AAA-ATPase, which normally assists SG clearance, is itself mutated in some ALS cases (Buchan et al., 2013 [9]).
Aging [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- face persistent, low-grade stressors:
These factors create conditions favoring persistent SGs that are difficult to disassemble, providing a continuous environment for pathological protein aggregation (Wolozin & Ivanov, 2019 [10]).
The strongest evidence linking SG pathology to neurodegeneration comes from [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- and [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--. Over 50% of genes implicated in ALS encode SG-associated proteins or regulators of SG dynamics:
[TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--: Cytoplasmic [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- inclusions—the pathological hallmark of ~97% of ALS and ~50% of FTD cases—colocalize with SG markers. ALS-linked [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- mutations accelerate SG maturation and liquid-to-solid transition (Li et al., 2013 [11]). Stress-induced [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- mobility loss can occur independently of visible SG formation, suggesting that aberrant phase transitions occur even before SG condensation (Gasset-Rosa et al., 2019 [12]).
[FUS[/entities/[fus[/entities/[fus[/entities/[fus--TEMP--/entities)--FIX--: ALS-linked FUS mutations impair nuclear import via [importin-β/Transportin-1], increasing cytoplasmic FUS concentration. This promotes aberrant FUS incorporation into SGs, accelerating their maturation to insoluble aggregates (Dormann et al., 2010 [13]).
[C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX--: The hexanucleotide repeat expansion in [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- is the most common genetic cause of ALS/FTD. The expansion product impairs SG dynamics through multiple mechanisms: (1) sense and antisense RNA foci sequester SG proteins; (2) [dipeptide repeat proteins from RAN translation] (particularly poly-GR and poly-PR) interact with SG components; and (3) loss of [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- protein function impairs autophagy-mediated SG clearance (Lee et al., 2016 [14]).
VCP/p97 mutations: Mutations in the valosin-containing protein (VCP) cause ALS, FTD, and inclusion body myopathy. VCP is an AAA-ATPase essential for SG clearance through granulophagy—the selective autophagic degradation of SGs (Buchan et al., 2013 [9]).
ATXN2: Intermediate-length polyglutamine expansions in ataxin-2 (ATXN2) are a risk factor for ALS. ATXN2 is a SG component, and its expanded polyQ form promotes persistent SG formation and enhanced [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- accumulation (Elden et al., 2010 [15]).
SG pathology contributes to [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- through several mechanisms:
[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- protein] interacts with SG components TIA-1, G3BP1, and TTP. Tau promotes SG formation, and conversely, SG formation enhances tau] misfolding and aggregation (Vanderweyde et al., 2016 [16]).
Pathological tau-positive [neurofibrillary tangles[/mechanisms/[neurofibrillary-tangles[/mechanisms/[neurofibrillary-tangles[/mechanisms/[neurofibrillary-tangles--TEMP--/mechanisms)--FIX-- in AD brains colocalize with TIA-1 and G3BP1, but the SG proteins show contrasting distributions: TIA-1 accumulates in tau tangles while G3BP1 is reduced in affected [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (Vanderweyde et al., 2012 [17]).
[Amyloid-β[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers trigger SG formation via oxidative stress, creating a feedforward loop where [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---induced SGs enhance tau pathology, and tau-SG interactions further impair neuronal proteostasis (Ash et al., 2014 [18]).
Mutant [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- protein] with expanded polyQ tracts alters SG dynamics and is found in SG-like condensates. The RNA-binding protein TIA-1 colocalizes with [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- aggregates in [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- brains.
[Spinocerebellar ataxias] with polyQ expansions (SCA1, SCA2, SCA3) also show altered SG dynamics. ATXN2 (SCA2) is a direct SG component, and its polyQ expansion promotes persistent SG formation.
eIF2α phosphatase activators: ISRIB, an integrated stress response inhibitor, prevents eIF2α phosphorylation-dependent SG formation without affecting the beneficial aspects of the ISR. ISRIB has shown efficacy in preclinical ALS/FTD models (Sidrauski et al., 2015 [19]).
DNAJ chaperone overexpression: J-domain proteins (DNAJB1, DNAJB2a, DNAJB4, DNAJB5) significantly reduce insoluble [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- in cellular models by maintaining SG fluidity and preventing maturation (Gu et al., 2023 [20]).
[autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- enhancement: Since granulophagy is the primary route for SG clearance, [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX---enhancing compounds (rapamycin, trehalose, [TFEB[/entities/[tfeb[/entities/[tfeb[/entities/[tfeb--TEMP--/entities)--FIX-- activators) may promote resolution of pathological SGs.
VCP/p97 modulators: Small molecules that enhance VCP-mediated SG extraction and delivery to the autophagy pathway.
Bait RNA therapy: Short synthetic RNAs that bind [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--'s RNA-recognition motif can prevent its aggregation within SGs by maintaining the protein in a soluble, native state (Mann et al., 2019 [21]).
[Antisense oligonucleotides (ASOs)[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--: ASOs targeting ATXN2 reduce SG formation and suppress [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- toxicity. Biogen's ATXN2-targeting ASO for ALS has entered clinical trials.
eIF2α kinase inhibitors: Selective inhibitors of PERK, HRI, or PKR may reduce pathological SG formation while preserving beneficial stress responses.
[GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX-- inhibitors: [GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX-- regulates SG dynamics, and its inhibition has shown some benefit in reducing SG persistence in cellular models.
Specificity of SG subtypes: Do different stressors generate SGs with distinct compositions, and are some subtypes more prone to pathological maturation?
Cell-type selectivity: Why do motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (in ALS) and cortical/frontal [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (in FTD) show [selective vulnerability] to SG pathology?
Prion-like spreading: Can pathological SGs or their fibrillar cores propagate between [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- via [prion-like mechanisms]?
Biomarker development: Can SG-derived species be detected in [cerebrospinal fluid or blood] as early biomarkers of disease?
Therapeutic window: At what point in disease progression does SG-targeted therapy become ineffective?
The study of Stress Granules In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 21 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 49%